Littlepage et al. [38] demonstrated that the AKT signaling pathway was downstream of ZNF217, and that triciribine, which is a pharmacological inhibitor of AKT activation, attenuated the growth of breast cancer in xenografted mice models expressing high ZNF217. The gene discussed is AKT1; the disease is breast carcinoma.